Neoplasms, Plasma Cell: all 2,314 studies
Page 17 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide MaintenanceStatus unknownNCT01685814Phase 3
- Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple MyelomaWithdrawnNCT01680796Phase 1
- Autologous Stem Cell Transplantation for Myeloma Patients Over 65 YearsStatus unknownNCT01671826
- Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaStatus unknownNCT01665014Phase 2
- Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1
- MLN9708 and Dexamethasone for High-Risk Smoldering Multiple MyelomaWithdrawnNCT01660997Phase 2
- A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed MyelomaCompletedNCT01660750Phase 1
- Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous TransplantationCompletedNCT01660633Phase 2
- Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma PatientsCompletedNCT01653106Not applicable
- Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceWithdrawnNCT01647165Phase 2
- BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple MyelomaCompletedNCT01638936Phase 1/2
- Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple MyelomaApproved for marketingNCT01632826
- Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple MyelomaCompletedNCT01622582
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple MyelomaStatus unknownNCT01619358
- Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple MyelomaTerminatedNCT01617213Phase 2
- Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin LymphomaTerminatedNCT01609816Phase 1
- Autophagy Induction After Bortezomib for MyelomaCompletedNCT01594242Early Phase 1
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Phase 2
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple MyelomaCompletedNCT01583283Phase 1
- XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone DiseaseCompletedNCT01582295Phase 1
- Safety and Pharmacokinetic Profile of CKD-581CompletedNCT01580371Phase 1
- Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)CompletedNCT01575925Phase 1
- Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple MyelomaCompletedNCT01572857
- Safety and Efficacy Study of High Dose Melphalan to Treat Multiple MyelomaStatus unknownNCT01572688Not applicable
- Imaging Studies and the Development of Multiple MyelomaWithdrawnNCT01571726Phase 2
- Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01568294Phase 1
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple MyelomaTerminatedNCT01555281Phase 1/2
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsStatus unknownNCT01554852Phase 3
- Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple MyelomaCompletedNCT01549431Phase 1
- Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple MyelomaStatus unknownNCT01541332Phase 1/2
- Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple MyelomaTerminatedNCT01537861Early Phase 1
- Viral Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01533194Phase 1
- Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 YearsStatus unknownNCT01532856Phase 3
- Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple MyelomaCompletedNCT01530594Phase 3
- Stem Cell Transplantation for Patients With Multiple MyelomaCompletedNCT01526096Phase 1
- Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple MyelomaStatus unknownNCT01522872Phase 1/2
- Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple MyelomaTerminatedNCT01518465Phase 2
- Bortezomib Consolidation TrialCompletedNCT01517724Phase 2
- Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01508416
- 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01503242Phase 1
- Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance TherapyWithdrawnNCT01501370Phase 2
- Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01497093Phase 1
- Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaWithdrawnNCT01492881Phase 2
- A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01485835Phase 1
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- ACVDL Treatment for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01481194Phase 2
- A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor CancersCompletedNCT01476137Phase 1
- Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in VitroCompletedNCT01472627
- A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple MyelomaTerminatedNCT01470131Phase 3
- A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple MyelomaCompletedNCT01464112Phase 1
- A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01464034Phase 1/2
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic TransplantationCompletedNCT01460420Phase 1/2
- A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01456689Phase 1
- Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic ProfileCompletedNCT01454297
- Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple MyelomaCompletedNCT01450215Phase 2
- Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) PatientsCompletedNCT01440582Phase 1
- Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple MyelomaCompletedNCT01440556
- Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)Status unknownNCT01435720Phase 1/2
- A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01432353Phase 1
- Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second LineCompletedNCT01430546
- Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT01428492Phase 1
- Pseudohyponatremia of Multiple Myeloma is True HyponatremiaStatus unknownNCT01425606
- Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedNCT01421524Phase 1
- Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell TransplantCompletedNCT01416246Not applicable
- Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic MalignanciesCompletedNCT01413568Phase 1/2
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple MyelomaCompletedNCT01410981
- Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple MyelomaWithdrawnNCT01410929Phase 4
- Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory DiseaseApproved for marketingNCT01410500
- Cyclophosphamide and Pulse Dexamethasone With Rapamycin or HydroxychloroquineCompletedNCT01396200Early Phase 1
- Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)CompletedNCT01394354Phase 1/2
- Protocol to Obtain Blood and Bone Marrow Samples for Myeloma ResearchTerminatedNCT01382615
- Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple MyelomaCompletedNCT01376401Phase 2
- Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT01372540Phase 1
- A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple MyelomaCompletedNCT01371227Phase 1
- Two Cycles of PAD Combination by AHCT in MMCompletedNCT01370434Phase 2
- Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing TreatmentsCompletedNCT01365559Phase 1/2
- Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT01359657Phase 1
- Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)CompletedNCT01352338Phase 1/2
- THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)CompletedNCT01341262Phase 2
- Study in Patients With Untreated Multiple Myeloma and Renal InsufficiencyCompletedNCT01337752Phase 2
- Phase II Study of Simvastatin for Relapsed/Refractory MyelomaWithdrawnNCT01332617Phase 2
- Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple MyelomaCompletedNCT01330173Phase 1
- SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple MyelomaWithdrawnNCT01329289Phase 2
- Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)Status unknownNCT01325896Phase 2
- A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) PatientsStatus unknownNCT01314625
- A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple MyelomaTerminatedNCT01309412Phase 1
- Study of BHQ880 in Patients With High Risk Smoldering Multiple MyelomaCompletedNCT01302886Phase 2
- Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT01301807Phase 1
- Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple MyelomaCompletedNCT01296503Phase 3
- Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131CompletedNCT01296204Phase 1
- Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCTCompletedNCT01286675Early Phase 1
- Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)CompletedNCT01279694Phase 1/2
- A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple MyelomaCompletedNCT01274403Phase 2
- Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple MyelomaCompletedNCT01272466Phase 1/2
- Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure PatientsCompletedNCT01270932Phase 2
- Role of BCL-B in Multiple MyelomaCompletedNCT01270009
- PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot StudyActive, not recruitingNCT01269593Early Phase 1